Engflag

Pethanol

Quick links to important sections

Pethanol

Pethanol_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pethanol

Property Description
Active ingredient Meperidine Hydrochloride (Pethidine)
Form Injectable solution, tablet, syrup
Pharmacological class Synthetic Opioid Analgesic
Common use Management of moderate to severe pain
Origin Synthetic (Man-made)

Pethanol is a powerful, prescription-only medication whose active component is Meperidine Hydrochloride, a substance recognized internationally as Pethidine. It is classified as a synthetic opioid analgesic, meaning it is a man-made compound engineered to relieve pain by acting directly on the central nervous system. This classification is vital for understanding its action; Meperidine belongs to the phenylpiperidine chemical class and functions as a pure opioid agonist.

This drug is typically supplied as a single-ingredient product, focusing its therapeutic effects solely on analgesia and sedation. The drug's synthetic origin confirms it is produced entirely through chemical synthesis. Pethanol is often used interchangeably with other trade names containing the same INN (International Nonproprietary Name) and is clinically recognized for its comparatively rapid onset of action when administered parenterally.

Pethanol's Available Forms and Primary Use

Pethanol (Meperidine) is typically supplied in several dosage forms to accommodate various clinical needs, including an injectable solution for acute relief and a tablet for oral administration. Its general therapeutic purpose is to provide effective pain management for moderate to severe pain.

Both oral and parenteral (injection) forms allow clinicians to select the most appropriate route of administration based on the urgency of the patient's discomfort. Beyond its potent role in reducing pain signals, this medication is also valued for its ability to induce concurrent sedation. This dual benefit makes it a common choice for use as a preoperative medication or an essential adjunct to anesthesia before medical or surgical procedures. Its use in obstetric analgesia (labor pain relief) has been a differentiating factor in its pharmacological history compared to other opioids.

What side effects are possible with Pethanol?

Pethanol, containing Meperidine Hydrochloride (Pethidine), has a safety profile documented in official prescribing information from government health authorities. Like all opioid analgesics, it carries risks that require careful consideration.

Serious and Life-Threatening Safety Patterns

The most critical safety concern is respiratory depression, which is considered greatest during the initiation of therapy or following a dosage increase. Other severe hazards documented in regulatory documents include circulatory depression, shock, cardiac arrest, and convulsions (seizures). A strictly documented safety constraint is the potential for a severe and occasionally fatal reaction when Pethanol is administered concurrently with, or within 14 days of, Monoamine Oxidase Inhibitors (MAOIs).

Officially Documented Adverse Reactions

The most frequently observed adverse reactions involve the central nervous system and the gastrointestinal tract. The table below outlines these and other documented effects by System Organ Class (SOC):

System Organ Class (SOC) Effects Most Frequently Observed
Nervous System Lightheadedness, Dizziness, Sedation, Sweating
Gastrointestinal Nausea, Vomiting, Dry mouth, Constipation

Other reactions listed in regulatory documents include euphoria, dysphoria, weakness, headache, confusion, tremor, miosis, hypotension, and urinary retention. The risk of opioid addiction, abuse, and misuse is a central regulatory constraint associated with this medication.

Special Population Considerations

Official labels include explicit cautions for specific patient groups. Geriatric patients (older adults) may exhibit increased sensitivity and risk of CNS effects like confusion. Patients with renal or hepatic impairment face an elevated risk of toxicity (e.g., seizures) due to the accumulation of the metabolite normeperidine, a risk that is also associated with extended/long-term use. Administration during labor carries the documented risk of causing respiratory depression in the newborn.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Pethanol (Meperidine Hydrochloride) defines overdose as a severe medical emergency primarily involving the Central Nervous System (CNS), Respiratory, and Cardiovascular systems. Any suspected overdose requires immediate contact with emergency services.

Documented Overdose Manifestations Severe Outcomes and Actions Required
Respiratory depression (slow/shallow breathing), somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and miosis. Apnea, circulatory collapse, and cardiac arrest are documented severe outcomes.
CNS excitability signs, including tremors and convulsions (seizures), are documented risks associated with the accumulation of the normeperidine metabolite. The primary action is to seek immediate medical attention.

The most critical risk is the progression of respiratory depression to apnea, which can lead to severe hypoxia and death. Regulator-mandated emergency response focuses on the reestablishment of a patent airway, assisted or controlled ventilation, and the administration of the specific opioid antagonist, Naloxone. Increased overdose susceptibility is noted in elderly and debilitated patients, and the risk of metabolite-related toxicity is higher in those with renal impairment. Hospital monitoring is required after initial reversal until spontaneous respiration is reliably re-established. The potential for Serotonin Toxicity is a specific regulatory concern when Pethanol is used concurrently with serotonergic agents.

Therapeutic Uses of Pethanol

Pethanol (Meperidine/Pethidine) is considered relevant in clinical settings, focused on providing symptomatic support across domains where patient distress and pain intensity are heightened. The medication is applied in situations involving certain distressing symptoms.

Symptom Management and Clinical Contexts

This medication is commonly used to address symptoms related to physical discomfort of moderate to severe intensity. It is relevant in conditions characterized by periods of heightened symptoms such as acute postoperative pain, visceral pain episodes like renal or biliary colic, and during obstetrical analgesia. In these scenarios, Pethanol contributes to easing the overall symptom load by offering symptomatic relief.

The medication is commonly used as a preoperative medication and support of anesthesia in situations involving heightened systemic burden. Furthermore, it may assist with managing postanesthetic shivering.

“The medication may provide supportive relief, helping patients cope more steadily with difficult episodes of intense discomfort.”

Quick Fact: Focus on Moderate to Severe Acute Pain Symptoms

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Pethanol (Meperidine/Pethidine) is generally approved for use in adults for acute, moderate-to-severe pain, including use as a preoperative medication and for obstetric analgesia. Use is contraindicated and must be avoided in several specific populations, as mandated by regulatory documents.

Category Official Regulatory Statement
Absolute Contraindication Patients who have received Monoamine Oxidase Inhibitors (MAOIs) within the past 14 days due to the risk of severe reactions [1.1, 1.3]. Also, patients with known hypersensitivity to the drug, severe respiratory depression, or paralytic ileus [1.2, 1.3].
Age-Related Rules Older adults require caution and a reduced initial dose because of increased sensitivity and risk of toxicity from the accumulating metabolite, normeperidine [1.2, 4.5]. Use in infants under 6 months is often not established or not recommended [2.2, 4.5].
Condition-Based Limits Use is strictly limited or contraindicated in patients with severe renal or hepatic impairment due to the accumulation of the neurotoxic metabolite, normeperidine [1.2, 3.2]. Extreme caution is required in patients with head injury, increased intracranial pressure, or preexisting convulsive disorders [1.1, 1.3].
Pregnancy/Lactation Not recommended during prolonged pregnancy due to the risk of Neonatal Opioid Withdrawal Syndrome [1.2, 1.3]. Monitoring of the infant for sedation and respiratory depression is required if the drug is used while breastfeeding [1.1].

Official labeling strictly reserves the medicine for acute episodes of pain and not for the treatment of chronic pain [1.1].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Pethanol (Meperidine) defines several clinically significant interaction patterns.

Formal Contraindications and Timing

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the risk of severe, unpredictable reactions, including Serotonin Syndrome. A mandatory time separation is required; Pethanol must not be administered within 14 days of stopping MAOI therapy.

Pharmacodynamic and CNS Risks

Pethanol exhibits pharmacodynamic interactions with other Central Nervous System (CNS) Depressants, including alcohol. The combination results in additive effects, significantly increasing the documented risk of profound sedation and life-threatening respiratory depression. The simultaneous use of Serotonergic Drugs (e.g., SSRIs, SNRIs) is officially associated with the risk of Serotonin Syndrome. Interactions with Skeletal Muscle Relaxants may also enhance neuromuscular blocking action.

Metabolic and Exposure Alteration

Pharmacokinetic interactions are documented involving the CYP3A4 and CYP2B6 metabolic pathways. Inhibitors of these enzymes may increase Pethanol plasma concentrations, potentially enhancing effects. Conversely, enzyme inducers may decrease plasma concentrations. Additionally, the label notes that substances such as Cimetidine and Ritonavir can reduce clearance or increase the formation of normeperidine, the toxic metabolite. This risk of normeperidine accumulation is explicitly heightened in patients with renal impairment. Interactions with Grapefruit or Grapefruit Juice may also increase Pethanol blood levels.

Mechanism of Action

How Pethanol Works: Mechanism of Action

Pethanol engages in the precise modulation of signaling pathways involved in heightened or dysregulated physiological responses. The drug targets specific molecular mechanisms to alter the transmission profile within affected biological systems.

Modulation of Receptor-Mediated Signaling

This domain covers Pethanol's interaction with specific membrane receptors, where it functions to either initiate or suppress signaling sequences. This engagement reduces excessive mediator activity, contributing to changes in the activity profile of affected signaling pathways.

Regulation of Downstream Enzyme Cascades

The molecule alters early molecular steps by influencing key enzymes within the targeted pathways. This intervention occurs in cascades where multiple layers of pathway activation are present, resulting in specific physiological adjustments downstream of pathway engagement.

Influence on Feedback Regulatory Mechanisms

This domain addresses Pethanol's effects in systems where specific transmitters dominate and pathway adjustments are required. By modifying feedback mechanisms influencing pathway control, the drug reduces the rate of activity increase in specific signaling pathways.

Dosage and Administration Information

How to Use Pethanol

Pethanol (Meperidine Hydrochloride/Pethidine) is administered via specific methods which define its usage patterns and preparation. Dosing principles emphasize individualized treatment with attention to the route, frequency, and patient-specific factors.

Official Administration and Forms

Administration is confined to Oral (tablet, oral solution), Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) routes. The injectable solution is also used for continuous infusion.

Route Standard Adult Dose Range Frequency/Timing
PO, IM, SC 50 mg to 150 mg Every 3 to 4 hours as needed
IV (Slow) 25 mg to 50 mg Every 3 to 4 hours as needed
Preoperative 50 mg to 100 mg (IM, SC) 30 to 90 minutes prior to procedure

The total dose for pain management must not exceed 600 mg in 24 hours. For obstetrical analgesia, doses of 50 mg to 100 mg may be repeated at 1 to 3 hour intervals.

Preparation and Specific Use Instructions

Administration technique requires specific adherence. Oral tablets must be swallowed whole and should not be crushed or chewed, while the oral solution must be mixed with half a glass of water prior to consumption. The intravenous solution must be injected very slowly, often requiring dilution.

Treatment duration is required to be the shortest possible, as the medication is not intended for chronic pain. Dose titration is mandatory, meaning the starting dose must be the lowest effective amount and adjusted according to individual response.

Population-Specific Rules: A reduced initial dose is mandated for older adults due to increased sensitivity and slower clearance. Similarly, dose reduction is a required principle for patients with renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pethanol (Meperidine)

The research record for Pethanol (Meperidine) primarily consists of clinical trials and comparative studies used in research exploring how symptoms change over time in acute, short-term settings. The evidence contributes to understanding symptom patterns and helps contextualize how patients reported their experience during the study period.

Evidence for Managing Moderate to Severe Acute Pain

The most comprehensive research base for Pethanol was structured around studies focusing on outcomes related to physical discomfort classified as moderate to severe. Randomized Controlled Trials (RCTs) and comparative clinical trials were the principal designs used in research exploring how symptoms change over time.

Research explored its use in contexts characterized by acute or disruptive episodes of pain, such as those associated with acute recovery periods or episodes of systemic imbalance. The main outcomes research examined were measurements of patient-reported shifts in symptom severity, the time until the start of observed change, and the duration of observed patterns. Findings describe patterns related to the scores measured during the study intervals. Some trials described patterns when Pethanol was compared to a placebo or to other medications.

Evidence for Use in Specialized Clinical Contexts

Research has explored Pethanol's use in several specialized settings, often involving outcomes related to physical discomfort and sedation. These are studies focusing on episodes where symptoms become more noticeable or require immediate intervention.

Research on Obstetrical Analgesia

Pethanol was evaluated in research exploring episodic symptom patterns in women experiencing active labor. Research examined patient-reported outcomes describing perceived discomfort and monitored outcomes related to the newborn's physiological status. Findings describe group patterns related to these measured outcomes, but evidence remains limited and heterogeneous.

Research on Postanesthetic Shivering

RCTs were evaluated in patients recovering from anesthesia in a post-surgical setting. Research examined outcomes monitoring physiological strain specifically related to shivering after anesthesia. Studies monitored the severity and frequency of shivering episodes and the time required to observe change. Research reported measurements of symptom patterns during this acute phase and examined the association between Pethanol administration and observed shifts in physiological strain.

Unanswered Questions and Research Gaps

Despite the existing research, there are several aspects where certainty remains low or where additional studies are needed to provide a fuller context to the evidence landscape. The most consistent limitation is that follow-up durations were short, with most studies concentrating on immediate results. Therefore, long-term outcomes are not fully established, particularly as the presence of its metabolite was observed in research. Comparative evidence with many of the newest available analgesics is lacking in large-scale modern trials. Furthermore, the evidence quality varies across studies due to the age of some core research, meaning findings describe group patterns but do not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Pethanol (FAQ)

Q: Does it make you sleepy?

Official product information, such as the prescribing label, reports drowsiness or somnolence (sleepiness) as a potential adverse reaction related to Pethanol's action on the central nervous system. The official label commonly includes warnings regarding the potential impairment of ability to drive or operate heavy machinery due to these effects.

Q: Is it safe long-term?

Regulatory documents specify the approved duration of treatment for Pethanol. These official sources contain detailed warnings and precautions that describe potential risks and outline the necessary oversight or considerations associated with using the medicine for prolonged periods beyond the labeled duration.

Q: Can children 2 years old use it?

The official product information specifies the approved pediatric age groups and the specific conditions for which Pethanol is indicated. If 2-year-olds are not included in the approved population, the regulatory information is specific to the approved age range and does not contain prescribing details for that younger group.

How should Pethanol be stored and disposed of?

Pethanol must be stored and handled with special care due to its classification as a highly flammable liquid and vapor, similar to alcohol-based substances. Store the product in its original, tightly closed container in a cool, dry, and well-ventilated area.

Storage and Stability

Keep Pethanol away from heat, sparks, open flames, and all sources of ignition. Labeled storage often requires protection from high temperatures (e.g., above 25 C). Stability data for specific product formulations may dictate an in-use period (e.g., use within X days after initial opening) for multi-dose products. Do not expose the container to direct sunlight.

Disposal

Do not dispose of Pethanol or its waste containers in the household trash or down the drain/sewer. The substance is considered hazardous waste and must be disposed of according to federal and local regulations for pharmaceutical waste, typically through an approved waste disposal contractor. Ensure all containers are sealed before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pethanol found in:

A-Z Index: